Quality Botanical Ingredients Introduces Tri-Xanthine -- Ephedra Substitute for Weight Loss and Energy Boost

OUTH PLAINFIELD, N.J.--June 25, 2003--Quality Botanical Ingredients, Inc. (QBI), a leading manufacturer, processor and supplier of bulk botanical materials and nutritional ingredients to the food, nutraceutical, pharmaceutical, cosmetic and pet food industries, introduced new Tri-Xanthine(TM), a safe and effective substitute for ephedra (or its natural form, mahuang) to promote weight loss and boost energy levels. QBI is a division of Health Sciences Group, Inc. (OTCBB: HESG).

Ephedra/mahuang was until recently the most popular non-prescription ingredient for weight loss supplements and food products. Of late, the substance has been blamed for serious health problems and even deaths, causing much of the industry to abandon it and some regulators to ban it.

Formulation experts at QBI went to work to find a safe alternative. They noted that mahuang is a thermogenic herb -- it speeds up the metabolism, increasing blood flow and the supply of oxygen and nutrients to the body. This results in improved cellular efficiency and higher energy. Thermogenic herbs also suppress appetite by directing the flow of blood away from the stomach, reducing hunger and appetite.

"To safely mimic the effect of ephedra/mahuang," says QBI president Joseph Schortz, "we created Tri-Xanthine -- a combination of three thermogenic extracts derived from cocoa beans, green tea and yerba mate. Tri-Xanthine is a water soluble powder that can be used in a wide variety of products -- drinks, tablets or capsules, snacks, energy bars or most any food product."

QBI is working with a number of food and supplement manufacturers, formulating new products that will be available in grocery and natural food stores soon.

John Sbordone, president of Connecticut ingredient broker MetaBev, Inc., said, "This is the most exciting new ingredient the industry's seen in a long time." Sbordone, who has several clients in the U.S. and Canada designing energy drinks and other products around Tri-Xanthine, added, "Consumers are less likely to suffer the extreme highs and lows of ephedra/mahuang products when they use Tri-Xanthene products. I think it'll be a winner."

QBI processes more than 500 herbs, dried fruits and vegetables, nutraceuticals and an extensive selection of concentrated herbal extracts, as well as standardized herbal extracts of guaranteed potency, in addition to various bioflavonoids, antioxidants and beehive products. In business for 20 years, QBI uses cryogenic (cold) processing at its New Jersey facility, and operates in accordance with voluntary food safety guidelines (called Good Manufacturing Practices) originally published by the U.S. Food & Drug Administration in 1997.

About Health Sciences Group, Inc.

Health Sciences Group, Inc. is an integrated provider of innovative products and services in the nutraceutical, pharmaceutical, and cosmeceutical industries offering value-added ingredients, bioactive formulations, and proprietary technologies used in nutritional supplements, functional foods and beverages, and skin care products. Subsidiaries include Quality Botanical Ingredients, a leading manufacturer and contract processor of bulk botanical materials and nutritional ingredients for the nutraceutical, pharmaceutical and cosmetic industries; XCEL Healthcare, a fully licensed, specialty compounding pharmacy delivering full service pharmacology solutions to customers with chronic ailments that require long-term therapy; and BioSelect Innovations, which develops and sells innovative, science-based products based on proprietary technologies in the areas of topical/transdermal drug delivery, cosmeceuticals, and integrative medicine to a global network of customers who manufacture and distribute compounded pharmaceuticals, functional foods, skin care products and cosmetics. For more information, visit www.HealthSciencesGroup.com.

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including without limitation, the independent authority of the special committee to act on the matters discussed, the successful negotiation of the potential acquisition and disposal of transactions described above, successful implementation of the company's business strategy and competition, any of which may cause actual results to differ materially from those described in the statements. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.